Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$85.18 - $108.78 $408,864 - $522,144
-4,800 Reduced 82.76%
1,000 $107,000
Q1 2024

May 15, 2024

BUY
$73.17 - $99.79 $285,363 - $389,181
3,900 Added 205.26%
5,800 $550,000
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $83,524 - $176,396
1,900 New
1,900 $175,000
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $174,662 - $230,000
4,600 Added 117.95%
8,500 $382,000
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $160,134 - $259,272
3,900 New
3,900 $170,000
Q1 2021

May 17, 2021

SELL
$90.71 - $108.28 $507,975 - $606,368
-5,600 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$92.08 - $124.48 $515,648 - $697,088
5,600 New
5,600 $628,000
Q2 2020

Aug 14, 2020

SELL
$57.09 - $79.27 $5,709 - $7,927
-100 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$48.11 - $82.22 $1.29 Million - $2.2 Million
-26,800 Reduced 99.63%
100 $6,000
Q4 2019

Feb 14, 2020

BUY
$66.73 - $82.59 $133,460 - $165,180
2,000 Added 8.03%
26,900 $2.16 Million
Q3 2019

Nov 14, 2019

BUY
$72.9 - $101.41 $1.72 Million - $2.39 Million
23,600 Added 1815.38%
24,900 $1.83 Million
Q2 2019

Aug 14, 2019

SELL
$73.54 - $97.8 $88,248 - $117,360
-1,200 Reduced 48.0%
1,300 $123,000
Q1 2019

May 15, 2019

BUY
$48.7 - $86.6 $121,750 - $216,500
2,500 New
2,500 $200,000
Q4 2018

Feb 14, 2019

SELL
$45.57 - $74.26 $255,192 - $415,856
-5,600 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$58.91 - $78.32 $394,697 - $524,744
-6,700 Reduced 54.47%
5,600 $437,000
Q2 2018

Aug 14, 2018

BUY
$60.96 - $101.18 $256,032 - $424,956
4,200 Added 51.85%
12,300 $781,000
Q1 2018

May 15, 2018

BUY
$73.28 - $102.95 $593,568 - $833,895
8,100 New
8,100 $743,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.47B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.